Anti-inflammatory and antiproliferative actions of PPAR-γ agonists on T lymphocytes derived from MS patients
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Peroxisomal proliferator-activated receptors (PPARs) belong to a nuclear receptor superfamily of ligand-activated transcription factors. The PPAR-γ isoform is expressed in human T lymphocytes, and oral administration of PPAR-γ agonists ameliorates the clinical course and histopathological features in experimental autoimmune encephalomyelitis, an animal model for multiple sclerosis, suggesting a potential role for PPAR-γ agonists in the treatment of autoimmune diseases. To assess a potential therapeutic role of PPAR-γ agonists in multiple sclerosis, we compared the immunomodulatory effects of the thiazolidinedione (TZD) drugs pioglitazone (PIO) and ciglitazone and the non-TZD PPAR-γ agonist GW347845 on human T leukemia cells (Jurkat cells) and phytohemagglutinin (PHA)-stimulated peripheral blood mononuclear cells (PBMCs) derived from 21 multiple sclerosis patients and 12 healthy donors. PIO, ciglitazone, and GW347845 suppressed PHA-induced T cell proliferation by 40–50% and secretion of interferon-γ and tumor necrosis factor α, by 30–50%. Inhibition of proliferation was increased to ∼80% and that of proinflammatory cytokine secretion, to 80–90% when PBMCs were first preincubated with PPAR-γ agonists and re-exposed at the time of PHA stimulation, indicating a sensitizing effect of PPAR-γ agonists. Inhibition of proliferation was also observed in the tetanus toxoid-specific T cell line KHS.TT2, albeit to a lesser extent. The antiproliferative effects of PIO and GW347845 were accompanied by a decrease of cell viability. Electron microscopy and Western blot analysis revealed DNA condensation and down-regulation of bcl-2, suggesting the induction of apoptosis in activated T lymphocytes. In summary, the data support the potential use of PPAR-γ agonists as immunomodulatory, therapeutic agents for autoimmune diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
Jiang, C., Ting, A. T., & Seed, B. (1998) · Nature · doi:10.1038/34184 · Cited by 2,899
The mechanisms of action of PPARs
Berger, J., & Moller, D. E. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.104018 · Cited by 2,659
The PPARs: From Orphan Receptors to Drug Discovery
Willson, T. M., Brown, P. J., Sternbach, D. D., & Henke, B. R. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990554g · Cited by 1,816 · cited 2×
“[7], reduces inflammatory gene expression and protects neurons from immunostimulated cell death [8–11].”
BackgroundCombs, C. K., Johnson, D. E., Karlo, J. C., Cannady, S. B., & Landreth, G. E. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-02-00558.2000 · Cited by 483
The role of PPARs in inflammation and immunity
Clark, R. B. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.71.3.388 · Cited by 337 · cited 3×
“Although the most pronounced, antiproliferative effects of the TZD derivatives ciglitazone and PIO peaked at concentrations of 10–100 M as described previously [12–17], induction of apoptotic cell death by PIO in single T cells was observed at 1 M PIO, indicating that treatment effects of PPAR- agonists are already de…”
BackgroundHeneka, M. T., L. Feinstein, D., Galea, E., Gleichmann, M., Wüllner, U., & Klockgether, T. (1999) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(99)00192-7 · Cited by 150
Self-citation
Cited by
HENEKA, M., & LANDRETH, G. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.04.016 · Cited by 317
Self-citationReceptor-independent actions of PPAR thiazolidinedione agonists: Is mitochondrial function the key?
Feinstein, D. L., Spagnolo, A., Akar, C., Weinberg, G., Murphy, P., Gavrilyuk, V., & Russo, C. D. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.03.033 · Cited by 275
Self-citationNegrotto, L., Farez, M. F., & Correale, J. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2015.4807 · Cited by 198
Neuroinflammation: a potential therapeutic target
Craft, J. M., Watterson, D. M., & Van Eldik, L. J. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.5.887 · Cited by 116
Molecular targets of non-steroidal anti-inflammatory drugs in neurodegenerative diseases
Lleo, A., Galea, E., & Sastre, M. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-6516-1 · Cited by 93
Self-citation
Metadata
- Authors
- Schmidt, S., Moric, E., Schmidt, M., Sastre, M., Feinstein, D. L., & Heneka, M. T.
- Venue
- Journal of Leukocyte Biology
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-12-04
- Volume
- 75
- Issue
- 3
- Pages
- 478-485
- ISSN
- 0741-5400 (ISSN-L)
- 1938-3673
- OpenAlex
- W2122655651
- Cited by
- 96
- References
- 6
- FWCI
- 2.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anti-inflammatory and antiproliferative actions of PPAR-γ agonists on T lymphocytes derived from MS patients. https://app.cochat.ai/papers/10.1189/jlb.0803402
- The paper
- Schmidt, S., Moric, E., Schmidt, M., Sastre, M., Feinstein, D. L., & Heneka, M. T. (2004). Anti-inflammatory and antiproliferative actions of PPAR-γ agonists on T lymphocytes derived from MS patients. Journal of Leukocyte Biology. https://doi.org/10.1189/jlb.0803402
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.